Novel clinical features of glycine receptor antibody syndrome
A series of 17 cases
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 25, 2019
- Accepted in final form May 16, 2019
- First Published July 1, 2019.
Author Disclosures
- Amanda L. Piquet, MD,
- Murtaza Khan, MD,
- Judith E.A. Warner, MD,
- Matthew P. Wicklund, MD,
- Jeffrey L. Bennett, MD, PhD,
- Maureen A. Leehey, MD,
- Lauren Seeberger, MD,
- Teri L. Schreiner, MD, MPH,
- M. Mateo Paz Soldan, MD, PhD and
- Stacey L. Clardy, MD, PhD
- Amanda L. Piquet, MD,
(1) Sanofi Genzyme, consultant on scientific advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Honoraria from MedLink
NONE
NONE
NONE
NONE
(1) Donation from the Drank family through the Children's Hospital of Colorado Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Murtaza Khan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith E.A. Warner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew P. Wicklund, MD,
1. Myonexus Therapeutics 2. Sarepta Therapeutics
NONE
NONE
Muscle & Nerve, Editorial board member, 2016 to present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Acceleron 2. Orphazyme Stock/Stock Options, Medical Equipment & Materials: 1. Myonexus Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey L. Bennett, MD, PhD,
Clene Neuroscience
NONE
NONE
Editorial Board, Journal of Neuro-ophthalmology Editorial Board, Multiple Sclerosis Journal Editorial Board, Neurology: Neuroimmunology & Neuroinflammation
(1) Compositions and Methods for the Treatment of Neuromyelitis Optica; novel blocking monoclonal therapy for neuromyelitis optica: PCT/US2012/034662
NONE
NONE
(1) EMD-Serono (2) Viela Bio (3) Clene Nanomedicine (4) Chugai Pharma USA (5) Genzyme (6) Frequency Therapeutics (7) Alexion Pharmaceuticals (8) Genentech
NONE
NONE
NONE
(1) Mallinckrodt Pharmaceuticals
NONE
NONE
(1) National Institutes of Health (NEI) (2) Guthy-Jackson Foundation
NONE
NONE
(1) Aquaporumab, rights for future royalty payments
NONE
NONE
NONE
- Maureen A. Leehey, MD,
NONE
NONE
(1) Parkinson Study Group, travel funding
NONE
NONE
NONE
NONE
(1) GLG, (2) Guidepoint Global, (3) Synapsus, (4) Expert Connect, (5) Schlesinger, (6) Palladian, (7) Connected Research & Consulting, (8) Trinity Partners, (9) Toronto Western Hospital, (10) Leerink, (11) Design Science Consulting, (12) Harper Global, (13) Gerson Lehman, (14) Medacorp, (15) Parkinson Study Group
NONE
NONE
NONE
(1) Adamas Pharmaceuticals, (2) US WorldMeds LLC, (3) Biogen, (4) Neuroderm, (5)
(1) The National Institute of Neurological Disorders and Stroke, (2) Colorado Department of Public Health and Environment,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lauren Seeberger, MD,
NONE
APDM Wearable Technologies-gifted wearable device for pilot Huntington disease study
1)Huntington Study Group- travel, for education chair position to annual meeting 2)Friedreich's Ataxia Research Alliance-travel, for training to be a site for natural history study
NONE
NONE
NONE
NONE
1) Reata Pharmaceuticals
NONE
NONE
NONE
1)Vaccinex Pharmaceuticals/Huntington Study Group 2)Biohaven Pharmaceuticals 3)Parkinson Study Group/Michael J. Fox Foundation 4)Intec Pharma
1) NeuroNext 105 NIH 2) ReadiSCA U01 NIH
NONE
1)Huntington Study Group-travel and hotel, annual meeting 2)Parkinson Study Group-hotel, annual meeting
NONE
NONE
NONE
NONE
NONE
NONE
- Teri L. Schreiner, MD, MPH,
NONE
NONE
Multiple Sclerosis Association of America, speaker honoraria Genentech, Speaker honoraria
NONE
NONE
NONE
NONE
ACI Clinical. I serve on the adjudication board for a randomized controlled trial of teriflunomide in pediatric MS patients.
NONE
NONE
NONE
NONE
NONE
NONE
National MS Society. I have received research funding for participation in the US Network of Pediatric MS Centers.
NONE
NONE
NONE
NONE
NONE
NONE
- M. Mateo Paz Soldan, MD, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen
(1) National Institutes of Health
NONE
(1) National Multiple Sclerosis Society, (2) Western Institute for Biomedical Research
NONE
NONE
NONE
NONE
NONE
NONE
- Stacey L. Clardy, MD, PhD
NONE
NONE
NONE
Section Editor, Neurology Podcast (July 2018-present) and Neurology Minute (March 2019-present)
NONE
One time honorarium related to Guest Editor of the Autoimmune Neurology issue of Seminars in neurology.
NONE
2-3 consulting phone calls per year, 1 hour maximum, by related to this paper, each $500 US or less. Proceeds support University Development activities and Dr. Clardy does not receive direct payment.
NONE
NONE
NONE
NONE
NONE
Research support from Western Institute for Biomedical Research (WIBR).
Transverse Myelitis Association and ARIA foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (A.L.P., M.K., M.P.W., J.L.B., M.A.L., L.S., T.L.S.), University of Colorado, Aurora; Department of Neurology (A.L.P., J.E.A.W., M.M.P.S., S.L.C.), University of Utah; Department of Ophthalmology (J.E.A.W.), Moran Eye Center, University of Utah, Salt Lake City; Department of Ophthalmology and Program in Neuroscience (J.L.B.), University of Colorado; Department of Neurology (T.L.S.), Children's Hospital Colorado, Aurora; and Department of Veterans Affairs (M.M.P.S., S.L.C.), George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT.
- Correspondence
Dr. Piquet Amanda.Piquet{at}ucdenver.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Clinical/Scientific Notes
PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODYM. Hutchinson, P. Waters, J. McHugh et al.Neurology, October 13, 2008 -
Clinical/Scientific Notes
Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disordersHarry Alexopoulos, Sofia Akrivou, Marinos C. Dalakas et al.Neurology, October 30, 2013 -
Articles
Progressive encephalomyelitis with rigidity and myoclonusGlycine and NMDA receptor antibodiesM.R. Turner, S.R. Irani, M.I. Leite et al.Neurology, July 20, 2011 -
Clinical/Scientific Notes
Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomyK. Clerinx, T. Breban, M. Schrooten et al.Neurology, January 17, 2011